Here’s the latest good and bad news about COVID-19 drugs
After vaccines, antivirals and a monoclonal antibody are the next line of defense.
By Tina Hesman Saey, Science News
Tags: National News, U.S. Centers for Disease Control and Prevention, tracking sites, Office of Infectious Diseases, John Farley, New England Journal of Medicine, drug resistance, COVID, COVID-19, pandemic, monoclonal antibodies, test-to-treat sites, Evusheld, antiviral drugs, Ritonavir, Paxlovid, National Institute of Allergy and Infectious Diseases, nirmatrelvir